Mighty Therapeutics has launched a Phase 4 study examining the efficacy of elamipretide for Barth syndrome, marking a significant milestone in patient treatment options.

Mighty Therapeutics, formerly Stealth BioTherapeutics, embraces its new name to celebrate the mitochondrial disease community, focusing on hope and innovative treatments.

Stealth BioTherapeutics unveils its Mito Assist Patient Support Program and a partnership with AnovoRx to distribute FORZINITY for Barth syndrome.

Stealth BioTherapeutics receives FDA accelerated approval for FORZINITY, marking a pivotal advancement in Barth Syndrome treatment options. This promises hope for many families.

Stealth BioTherapeutics announces the FDA's acceptance of their NDA resubmission for elamipretide, targeting Barth syndrome and offering hope for treatment.

Stealth BioTherapeutics has resubmitted a New Drug Application for elamipretide to the FDA for the treatment of Barth syndrome, a rare genetic disorder.

Stealth BioTherapeutics is adjusting its strategy for elamipretide after FDA's delayed drug approval for Barth syndrome, offering new hope.

Stealth BioTherapeutics announces a delay in FDA action on its treatment for Barth syndrome, a rare mitochondrial disease affecting children globally. Stay informed!

Stealth BioTherapeutics announced that the FDA extended the PDUFA action date for elamipretide for Barth syndrome treatment to April 2025.